Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIFC NASDAQ:AVIR NASDAQ:CGC NASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$1.06+11.1%$1.17$0.73▼$10.95$134.16M1.693.51 million shs1.18 million shsAVIRAtea Pharmaceuticals$5.57-1.4%$5.56$2.45▼$6.45$446.17M0.38471,659 shs22,734 shsCGCCanopy Growth$1.15-0.4%$1.07$0.84▼$2.38$462.72M0.7811.75 million shs1.30 million shsRGNXREGENXBIO$10.05-1.7%$8.82$6.89▼$16.19$518.73M1.12871,038 shs280,102 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma+15.71%+8.32%-18.10%-38.31%-83.36%AVIRAtea Pharmaceuticals+0.89%+4.05%-3.75%+40.55%+101.79%CGCCanopy Growth+6.48%+5.50%+12.75%+6.48%-10.16%RGNXREGENXBIO+10.85%+21.67%+16.14%-0.39%+29.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$1.06+11.1%$1.17$0.73▼$10.95$134.16M1.693.51 million shs1.18 million shsAVIRAtea Pharmaceuticals$5.57-1.4%$5.56$2.45▼$6.45$446.17M0.38471,659 shs22,734 shsCGCCanopy Growth$1.15-0.4%$1.07$0.84▼$2.38$462.72M0.7811.75 million shs1.30 million shsRGNXREGENXBIO$10.05-1.7%$8.82$6.89▼$16.19$518.73M1.12871,038 shs280,102 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma+15.71%+8.32%-18.10%-38.31%-83.36%AVIRAtea Pharmaceuticals+0.89%+4.05%-3.75%+40.55%+101.79%CGCCanopy Growth+6.48%+5.50%+12.75%+6.48%-10.16%RGNXREGENXBIO+10.85%+21.67%+16.14%-0.39%+29.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFCALT5 Sigma 1.00SellN/AN/AAVIRAtea Pharmaceuticals 2.50Moderate BuyN/AN/ACGCCanopy Growth 2.00HoldN/AN/ARGNXREGENXBIO 2.70Moderate Buy$27.50173.63% UpsideCurrent Analyst Ratings BreakdownLatest AIFC, CGC, RGNX, and AVIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026AVIRAtea Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026CGCCanopy Growth Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy3/17/2026CGCCanopy Growth ATB Cormark Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Moderate Buy3/9/2026RGNXREGENXBIO HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$32.00 ➝ $30.003/5/2026RGNXREGENXBIO Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$18.00 ➝ $17.002/10/2026RGNXREGENXBIO HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$34.00 ➝ $32.002/10/2026RGNXREGENXBIO Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$27.002/10/2026RGNXREGENXBIO UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$18.002/10/2026RGNXREGENXBIO The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$14.00 ➝ $12.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFCALT5 Sigma$24.84M5.40N/AN/A$9.07 per share0.12AVIRAtea PharmaceuticalsN/AN/AN/AN/A$3.53 per shareN/ACGCCanopy Growth$225.65M2.05N/AN/A$1.90 per share0.60RGNXREGENXBIO$170.44M3.04N/AN/A$2.03 per share4.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFCALT5 Sigma-$344.51MN/AN/AN/AN/A-1,386.90%-50.52%-45.05%N/AAVIRAtea Pharmaceuticals-$158.35M-$1.94N/AN/AN/AN/A-46.34%-42.52%5/12/2026 (Estimated)CGCCanopy Growth-$429.86M-$1.30N/AN/AN/A-94.39%-46.85%-28.95%5/29/2026 (Estimated)RGNXREGENXBIO-$193.88M-$3.76N/AN/AN/A-113.75%-103.12%-37.83%5/11/2026 (Estimated)Latest AIFC, CGC, RGNX, and AVIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q4 2026CGCCanopy Growth-$0.06N/AN/AN/A$53.43 millionN/A5/12/2026Q1 2026AVIRAtea Pharmaceuticals-$0.60N/AN/AN/A$22.42 millionN/A5/11/2026Q1 2026RGNXREGENXBIO-$1.36N/AN/AN/A$25.84 millionN/A4/11/2026Q4 2025AIFCALT5 SigmaN/A-$6.19N/A-$6.19N/A$5.37 million3/5/2026Q4 2025AVIRAtea Pharmaceuticals-$0.49-$0.57-$0.08-$0.57N/AN/A3/5/2026Q4 2025RGNXREGENXBIO-$1.01-$1.30-$0.29-$1.30$45.48 million$30.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIFCALT5 SigmaN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFCALT5 Sigma0.010.570.57AVIRAtea PharmaceuticalsN/A7.827.82CGCCanopy Growth0.305.344.26RGNXREGENXBION/A2.382.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFCALT5 Sigma6.27%AVIRAtea Pharmaceuticals86.67%CGCCanopy Growth3.33%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipAIFCALT5 Sigma0.21%AVIRAtea Pharmaceuticals18.10%CGCCanopy Growth0.16%RGNXREGENXBIO14.22%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIFCALT5 Sigma170127.17 million126.90 millionN/AAVIRAtea Pharmaceuticals7080.03 million65.54 millionOptionableCGCCanopy Growth3,150404.12 million403.48 millionOptionableRGNXREGENXBIO37051.62 million44.28 millionOptionableAIFC, CGC, RGNX, and AVIR HeadlinesRecent News About These CompaniesREGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting4 hours ago | prnewswire.comREGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular DystrophyMay 6 at 7:05 AM | prnewswire.comREGENXBIO (RGNX) Expected to Announce Quarterly Earnings on MondayMay 4 at 12:09 PM | marketbeat.comKaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law ViolationsApril 28, 2026 | theglobeandmail.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 26, 2026 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Shares Pass Below 200-Day Moving Average - Should You Sell?April 22, 2026 | marketbeat.comREGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNXApril 14, 2026 | prnewswire.comBronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor HarmApril 14, 2026 | finanznachrichten.deRGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud LawsuitApril 14, 2026 | prnewswire.comRGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their RightsApril 14, 2026 | businesswire.comBronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor HarmApril 14, 2026 | newsfilecorp.comNCLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026April 14, 2026 | businesswire.comRGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law FirmApril 14, 2026 | prnewswire.comPortnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. InvestorsApril 14, 2026 | globenewswire.comFaruqi & Faruqi, LLP Highlights Class Action Against REGENXBIO (RGNX) and Upcoming Lead Plaintiff Deadline of April 14, 2026April 13, 2026 | newsfilecorp.comNREGENXBIO DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNXApril 13, 2026 | newsfilecorp.comNLevi & Korsinsky, LLP: RGNX Disclosure Timeline Reveals Pattern of Alleged Investor HarmApril 13, 2026 | globenewswire.comRGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 13, 2026 | globenewswire.comRGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 12, 2026 | prnewswire.comREGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNXApril 12, 2026 | globenewswire.comREGENXBIO DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNXApril 11, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIFC, CGC, RGNX, and AVIR Company DescriptionsALT5 Sigma NASDAQ:AIFC$1.06 +0.11 (+11.05%) As of 10:59 AM EasternALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Atea Pharmaceuticals NASDAQ:AVIR$5.57 -0.08 (-1.42%) As of 11:17 AM Eastern This is a fair market value price provided by Massive. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Canopy Growth NASDAQ:CGC$1.14 -0.01 (-0.43%) As of 11:18 AM Eastern This is a fair market value price provided by Massive. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.REGENXBIO NASDAQ:RGNX$10.05 -0.17 (-1.66%) As of 11:18 AM Eastern This is a fair market value price provided by Massive. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Fairy Dust Works: Disney's Stock Price Rises as Business Accelerates Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
